The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, ...

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...

Once prostate cancer no longer responds to hormonal therapy, the cancer is called castration-resistant. Find out which ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

Randee’s cancer had metastasized. When her doctor tested her for the PIK3CA gene mutation, she was able to make informed ...

Recent phase 2 data support combination treatment with samuraciclib for those with HR+ advanced breast cancer following prior ...

Researchers have discovered a set of alterations in the structure and cellular makeup of breast connective tissue – known as ...

Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group Between April 2019 and October 2022, 136 and 62 patients were randomly assigned to ...

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

Abbreviations: AI, aromatase inhibitor; ER, estrogen receptor; LHRH, luteinizing hormone-releasing hormone; OFS, ovarian function suppression; PR, progesterone receptor; y, years. *No evidence on ...